News Moderna and Merck expand partnership to develop new cancer v... Moderna and Merck & Co have expanded their partnership to develop and commercialise novel personalised messenger RNA (mRNA) cancer vaccines.
News Merck shows canny cancer strategy in $5.76bn Eisai milestone... Firms will co-develop Lenvima and Keytruda combinations
News Its Herceptin biosimilar nearing launch, Celltrion begins wo... South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda.
News Keytruda approved for bladder cancer in Europe, first to pro... Merck Sharp & Dohme’s Keytruda has been approved in Europe for metastatic urothelial carcinoma, a move which helps it catch up with its immunotherapy rivals.
News FDA probes blood cancer immunotherapy safety Regulator reviewing combination therapy safety after issue with Keytruda
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.